List view / Grid view
19 January 2016 | By Victoria White
In acquiring Biotie for approximately $363 million, Acorda will obtain worldwide rights to tozadenant, an oral adenosine A2a receptor antagonist currently in Phase 3 development in Parkinson’s disease...
12 January 2016 | By Victoria White
An analyst at GBI Research states that the pipeline for the disease is highly active, consisting of 365 programmes across all stages of development, and a diverse range of molecular targets...
19 October 2015 | By Victoria White
Nilotinib, a treatment for leukaemia, improved cognition, motor skills and non-motor function in patients with Parkinson's disease in a Phase I clinical trial...
21 July 2015 | By Victoria White
A Phase 3 study of tozadenant in patients with Parkinson's disease experiencing levodopa related end-of-dose "wearing-off" has started...
2 July 2015 | By Victoria White
The Parkinson’s disease treatment market value across eight major countries will reach $4.7 billion by 2022, says GlobalData...
15 June 2015 | By Victoria White
A Phase I/IIa study of NTCELL, an regenerative cell therapy being studied as a disease-modifying agent in Parkinson’s disease, has met its endpoints...
8 May 2015 | By
The FDA has lifted the clinical hold on clinical studies of ND0612H and ND0612L, NeuroDerm's product candidates for the treatment of Parkinson’s disease...
1 April 2015 | By Victoria White
NeuroDerm has announced that updated results from the Phase II Study of ND0612L will be presented at the American Academy of Neurology 67th Annual Meeting...
20 February 2015 | By Biotie
Biotie has announced further detail on its clinical development plan for tozadenant, an adenosine A2a antagonist in development for Parkinson's disease (PD)...
23 September 2014 | By nLife Therapeutics
The funding will help characterize the mechanism of action of nLife’s lead compound NLF-PD-1233 in a Parkinson disease model and find a proper dose to engage clinical development...
26 August 2014 | By Actavis
Actavis plc confirmed that it has filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking approval to market Rotigotine Extended-release Transdermal Film, 1 mg/24 hr, 2mg/24 hr, 3 mg/24hr, 4 mg/24 hr, 6mg/24hr, and 8 mg/24 hr...
9 June 2014 | By Teva
Teva Pharmaceutical Industries Ltd. announced the U.S. Food and Drug Administration has expanded the indication for AZILECT® (rasagiline tablets)...
20 May 2014 | By Lundbeck
H. Lundbeck A/S is involved in new research on Parkinson’s disease, which may be the first step towards a new and significantly improved treatment of the debilitating and devastating disease...
6 May 2014 | By H. Lundbeck A/S
H. Lundbeck A/S has once again received support and recognition for its research on Parkinson’s disease through a grant from The Michael J. Fox Foundation for Parkinson’s Research...
14 October 2013 | By H. Lundbeck A/S
The Michael J. Fox Foundation has donated 5.5 million kroner to two Danish research projects in Parkinson's disease...
